Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions

Zhu, Yanan; Wu, Juan; Wang, Jun; Ma, Xiaochi; Wu, Kaihua; Wang, Fangyu

doi:10.15537/smj.2023.44.8.20230231

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, several studies employing different analytical technologies have reported varying sensitivities and specificities, along with different cut-off values. More recently, in a cohort of patients suffering from early GC and intraepithelial neoplasia, Yanan et al reported a decrease in PGI and p27 and an increase in G-17 levels via the aggravation of severity, thus proposing those serum markers for the diagnosis of early GC [157]. In a study with 275 GC and 275 healthy patients enrolled, the risk classification of GC was improved by adopting new PG criteria (PGII ≥ 10 ng/mL or PGI/II ≤ 5) with the addition of an H. pylori antibody test and reduced instances of GC cases being misclassified as low risk [158].…”

Section: Serum Protein Marker Currently Used For Gastric Preneoplasti...mentioning

confidence: 99%

Circulating Proteins as Diagnostic Markers in Gastric Cancer

Repetto,

Vettori,

Steffan

et al. 2023

IJMS

View full text Add to dashboard Cite

Gastric cancer (GC) is a highly malignant disease affecting humans worldwide and has a poor prognosis. Most GC cases are detected at advanced stages due to the cancer lacking early detectable symptoms. Therefore, there is great interest in improving early diagnosis by implementing targeted prevention strategies. Markers are necessary for early detection and to guide clinicians to the best personalized treatment. The current semi-invasive endoscopic methods to detect GC are invasive, costly, and time-consuming. Recent advances in proteomics technologies have enabled the screening of many samples and the detection of novel biomarkers and disease-related signature signaling networks. These biomarkers include circulating proteins from different fluids (e.g., plasma, serum, urine, and saliva) and extracellular vesicles. We review relevant published studies on circulating protein biomarkers in GC and detail their application as potential biomarkers for GC diagnosis. Identifying highly sensitive and highly specific diagnostic markers for GC may improve patient survival rates and contribute to advancing precision/personalized medicine.

show abstract

Section: Serum Protein Marker Currently Used For Gastric Preneoplasti...mentioning

confidence: 99%

Circulating Proteins as Diagnostic Markers in Gastric Cancer

Repetto,

Vettori,

Steffan

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Study on the clinical efficacy of 14-day vonoprazan-based triple regimen in obese patients with Helicobacter pylori infection

Li,

Yan,

Dai

et al. 2024

Journal of Chemotherapy

View full text Add to dashboard Cite

ILF2 protein is a promising serum biomarker for early detection of gastric cancer

Liu,

Wang,

Liu

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Our previous small-sample study indicated that serum levels of interleukin enhancer binding factor 2 (ILF2) may have the potential for gastric cancer (GC) detection. The present study was conducted to further validate the diagnostic value of serum ILF2 protein for GC. Methods Serum specimens and clinical data were collected from patients with GC ( n = 99) or benign gastric disease (BGD) ( n = 49) and healthy controls (HC) ( n = 51). Serum ILF2 levels were measured using enzyme-linked immunosorbent assay. The diagnostic performance of ILF2 was evaluated using the area under the receiver operating characteristic curve (AUC). The independence and synergy of ILF2 in GC diagnosis were analyzed by modeling with conventional blood indicators. Results The median serum ILF2 level was higher in the GC group (227.8ng/mL) than in the BGD group (72.0ng/mL) and the HC group (56.8ng/mL) ( p < 0.001), and no significant difference across GC subgroups. The AUCs of ILF2 were 0.915 (95%CI 0.873–0.957) for GC vs. HC, 0.854 (95%CI 0.793–0.915) for GC vs. BGD, 0.885 (95%CI 0.841–0.929) for GC vs. BGD + HC, and 0.888 (95% CI 0.830–0.945) for TNM I stage GC vs. BGD + HC, outperforming conventional blood indicators (corresponding AUCs ranging from 0.641 to 0.782). ILF2 was independent of and synergistic with conventional blood indicators in GC diagnosis, and a simple diagnostic model based on ILF2 and red blood cell count improved the diagnostic performance, with positive rates of approximately 90% in various subgroups of GC. Conclusions Serum ILF2 protein is a novel and potential serum biomarker for the detection of GC, especially for early GC.

show abstract

Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions

Cited by 6 publications

References 22 publications

Circulating Proteins as Diagnostic Markers in Gastric Cancer

Circulating Proteins as Diagnostic Markers in Gastric Cancer

Study on the clinical efficacy of 14-day vonoprazan-based triple regimen in obese patients with Helicobacter pylori infection

ILF2 protein is a promising serum biomarker for early detection of gastric cancer

Contact Info

Product

Resources

About